With nirmatrelvir (Paxlovid) and molnupiravir not yet available, and the most widely used MAbs lacking activity against Omicron (+ other issues), is it time to bump up fluvoxamine at least to "consider use" status on the treatment guidelines? Two well-done RCTs show benefit.
@PaulSaxMD
I really think so… can still refer pt to mab infusion but while waiting (anticipate there might be shortage of sotrov soon for obvious reason?)
@PaulSaxMD
Yes. I'd look at fluvoxamine, inhaled steroids or colchicine in that order and depending on patient factors like drug interactions and comorbidities
@PaulSaxMD
NIH guideline recs & summary on fluvoxamine and inhaled steroids certainly no ringing endorsement and points out important limitations of the studies:
@PaulSaxMD
While the effects where modest both trials - showed benefit although with some less than key endpoints. The downside risk is low and there is not an interaction with ritonavir if that becomes available in the paxlovid regimen.
@PaulSaxMD
Fluvoxamine belonging to the class of SSRI’s is a potent CYP 3A4 inhibitor, which can cause an increase in the levels of many other meds not to mention QT prolongation. Also has a black box warning for risk of suicide in adolescents. Would have to use extreme caution .
@PaulSaxMD
@pash22
More recent RCTs confirm that high titer CP given early works, Hybrid plasma from those who have been infected & vaxed covers variants. There will more data early this week.
@PaulSaxMD
Tell me why doctors didn't tell HTLV-III/AIDS patients alcohol in a small amount can keep you alive? Instead, it was said nothing on shelves worked.
@PaulSaxMD
Available in India and with the unavoidable surge from Omicron soon consider having on hand for those with underlying disease.
Screenshot of the TOGETHER trial website page with dealing with results of Fluvoxamine in early COVID-19.